<DOC>
	<DOCNO>NCT00803842</DOCNO>
	<brief_summary>A side effect occur majority patient take erlotinib ( Tarceva® ) consist skin rash . Sometimes , symptom associate rash necessitate erlotinib dose reduction discontinuation . Some physician successfully treat erlotinib-induced rash doxycycline . At time , observe patient develop erlotinib rash , cancer respond good erlotinib treatment . This research study design determine well doxycycline treat erlotinib rash whether doxycycline affect blood level erlotinib .</brief_summary>
	<brief_title>Erlotinib Pharmacokinetics During Doxycycline Treatment Erlotinib-induced Rash</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Males females 18 year age old . Subjects must start Tarceva® therapy within three ( 3 ) day trial enrollment . Patients must sign informed consent prior registration study . Currently receive erlotinib therapy 150 mg per day locally advance metastatic NSCLC . Patients male female reproductive potential ( ie , menopausal less 1 year surgically sterilize ) must utilize barrier method combination spermicidal agent contraception engage sexual intercourse . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration . Allergy tetracycline . Use concurrent agent papulopustular rash . Currently receive anticancer agent erlotinib . Inability interrupt antibiotic therapy . Current use topical steroid Current use systemic immunosuppressant ( e.g. , methotrexate , cyclosporine , azathioprine , mycophenolate mofetil ) Photosensitivity lupus erythematosus . Active gastroesophageal reflux disease . Women positive pregnancy test lactate history . ECOG performance status ≤3 . Self report current smoke history smoking within 60 day screen , positive urine cotinine test . Current use agent know strong inducer inhibitor CYTP3A4 : inhibitor : atazanavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfi navir , ritonavir , saquinavir , telithromycin , troleandomycin ( TAO ) , voriconazole , grapefruit grapefruit juice inducer : rifampicin , rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital , St. John 's Wort Impaired hepatic function ( ≤ 30 day randomization ) : Alkaline phosphatase &gt; 3x ULN Aspartate aminotransferase ( AST ) &gt; x ULN Alanine aminotransferase ( ALT ) &gt; 3 x ULN Total Bilirubin &gt; 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>erlotinib</keyword>
	<keyword>rash</keyword>
	<keyword>supportive care</keyword>
</DOC>